Combination of nanoparticle-based therapeutic vaccination and transient ablation of regulatory T cells enhances anti-viral immunity during chronic retroviral infection.

2.50
Hdl Handle:
http://hdl.handle.net/10033/609566
Title:
Combination of nanoparticle-based therapeutic vaccination and transient ablation of regulatory T cells enhances anti-viral immunity during chronic retroviral infection.
Authors:
Knuschke, Torben; Rotan, Olga; Bayer, Wibke; Sokolova, Viktoriya; Hansen, Wiebke; Sparwasser, Tim ( 0000-0001-5645-902X ) ; Dittmer, Ulf; Epple, Matthias; Buer, Jan; Westendorf, Astrid M
Abstract:
Regulatory T cells (Tregs) have been shown to limit anti-viral immunity during chronic retroviral infection and to restrict vaccine-induced T cell responses. The objective of the study was to assess whether a combinational therapy of nanoparticle-based therapeutic vaccination and concomitant transient ablation of Tregs augments anti-viral immunity and improves virus control in chronically retrovirus-infected mice. Therefore, chronically Friend retrovirus (FV)-infected mice were immunized with calcium phosphate (CaP) nanoparticles functionalized with TLR9 ligand CpG and CD8(+) or CD4(+) T cell epitope peptides (GagL85-93 or Env gp70123-141) of FV. In addition, Tregs were ablated during the immunization process. Reactivation of CD4(+) and CD8(+) effector T cells was analysed and the viral loads were determined.
Affiliation:
TWINCORE, Centre for Experimental and Clinical Medicine, 30625 Hannover, Germany.
Citation:
Combination of nanoparticle-based therapeutic vaccination and transient ablation of regulatory T cells enhances anti-viral immunity during chronic retroviral infection. 2016, 13:24 Retrovirology
Journal:
Retrovirology
Issue Date:
2016
URI:
http://hdl.handle.net/10033/609566
DOI:
10.1186/s12977-016-0258-9
PubMed ID:
27076190
Type:
Article
Language:
en
ISSN:
1742-4690
Appears in Collections:
publications of the TwinCore unit Infection immunology

Full metadata record

DC FieldValue Language
dc.contributor.authorKnuschke, Torbenen
dc.contributor.authorRotan, Olgaen
dc.contributor.authorBayer, Wibkeen
dc.contributor.authorSokolova, Viktoriyaen
dc.contributor.authorHansen, Wiebkeen
dc.contributor.authorSparwasser, Timen
dc.contributor.authorDittmer, Ulfen
dc.contributor.authorEpple, Matthiasen
dc.contributor.authorBuer, Janen
dc.contributor.authorWestendorf, Astrid Men
dc.date.accessioned2016-05-17T14:42:26Zen
dc.date.available2016-05-17T14:42:26Zen
dc.date.issued2016en
dc.identifier.citationCombination of nanoparticle-based therapeutic vaccination and transient ablation of regulatory T cells enhances anti-viral immunity during chronic retroviral infection. 2016, 13:24 Retrovirologyen
dc.identifier.issn1742-4690en
dc.identifier.pmid27076190en
dc.identifier.doi10.1186/s12977-016-0258-9en
dc.identifier.urihttp://hdl.handle.net/10033/609566en
dc.description.abstractRegulatory T cells (Tregs) have been shown to limit anti-viral immunity during chronic retroviral infection and to restrict vaccine-induced T cell responses. The objective of the study was to assess whether a combinational therapy of nanoparticle-based therapeutic vaccination and concomitant transient ablation of Tregs augments anti-viral immunity and improves virus control in chronically retrovirus-infected mice. Therefore, chronically Friend retrovirus (FV)-infected mice were immunized with calcium phosphate (CaP) nanoparticles functionalized with TLR9 ligand CpG and CD8(+) or CD4(+) T cell epitope peptides (GagL85-93 or Env gp70123-141) of FV. In addition, Tregs were ablated during the immunization process. Reactivation of CD4(+) and CD8(+) effector T cells was analysed and the viral loads were determined.en
dc.language.isoenen
dc.titleCombination of nanoparticle-based therapeutic vaccination and transient ablation of regulatory T cells enhances anti-viral immunity during chronic retroviral infection.en
dc.typeArticleen
dc.contributor.departmentTWINCORE, Centre for Experimental and Clinical Medicine, 30625 Hannover, Germany.en
dc.identifier.journalRetrovirologyen

Related articles on PubMed

This item is licensed under a Creative Commons License
Creative Commons
All Items in HZI are protected by copyright, with all rights reserved, unless otherwise indicated.